현재가
목표 주가
Revance Therapeutics, Inc., a biotechnology company, is dedicated to the development, manufacture, and marketing of neuromodulators for various aesthetic and therapeutic indications in the United States and international...|
e.g. Promoter holding
Loading chart...
애널리스트 컨센서스 기준 EPS 및 매출 전망.
| Metric (B) | FY 2023 | FY 2023 | FY 2023 | FY 2023 | FY 2024 | FY 2024 | FY 2024 | FY 2024 | FY 2025 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| $-0.70 | $-0.78 | $-0.90 | $-0.72 | $-0.75 | $-0.53 | $-0.38 | $-1.64 | $-0.30 | $-1.01 | |
| 0.05 | 0.06 | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 | 0.26 | 0.07 | 0.33 | |
| -1.4% | -1.3% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -8.3% | +0.0% | -8.2% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | GGalectin T... | GALT | $307.59M | — | 207.70 | — | — | -3,728.00% | — |
| 2. | PPhathom Ph... | PHAT | $492.63M | — | 25.37 | -30.20% | -9.26% | -3,489.00% | 71.10% |
| 3. | RCartesian... | RNAC | $193.69M | — | 31.26 | — | -10,009.00% | -7,029.00% | -92.90% |
| 4. | CCelularity... | CELU | $20.45M | — | 9.89 | -245.70% | -254.00% | -6,367.00% | -5.30% |
| 5. | AArmata Pha... | ARMP | $143.94M | — | 2.11 | — | -461.80% | -3,439.00% | 173.60% |
연결 기준 (백만 단위) / 별도 보기 가능
| Quarter (M) | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 |
|---|---|---|---|---|---|---|---|---|
Revenue | 49.92 | 49.33 | 58.13 | 56.78 | 69.8 | 51.94 | 65.39 | 59.88 |
COGS | 23.52 | 16.17 | 21.31 | 19.41 | 18.89 | 16.89 | 19.06 | 17.63 |
Gross Profit | 26.41 | 33.16 | 36.83 | 37.36 | 50.91 | 35.04 | 46.32 | 42.25 |
Gross Profit % | 52.9% | 67.22% | 63.35% | 65.81% | 72.94% | 67.48% | 70.85% | 70.55% |
| 101.03 | 91.19 | 102.33 | 82.74 | 104.02 | 81.11 | 80.9 | 74.5 | |
EBIT | -74.62 | -58.03 | -65.5 | -139.29 | -53.11 | -46.06 | -34.58 | -32.26 |
OPM % | -149.48% | -117.64% | -112.67% | -245.34% | -76.09% | -88.69% | -52.88% | -53.87% |
Non-Operating Income | -71.33 | -1.76 | -1.82 | -1.58 | -2.59 | -3.46 | -2.89 | -4.36 |
PBT | -145.95 | -59.79 | -67.32 | -140.88 | -55.7 | -49.52 | -37.47 | -36.62 |
Income Tax | -1.4 | 6.26 | -0.06 | 0.3 | 1.38 | 3.63 | 0 | -1.5 |
Tax Rate % | 0.96% | -10.47% | 0.1% | -0.21% | -2.47% | -7.32% | 0% | 4.1% |
Net Income | -144.55 | -66.05 | -67.32 | -141.18 | -55.7 | -53.15 | -37.47 | -35.12 |
NPM % | -289.56% | -133.89% | -115.8% | -248.65% | -79.8% | -102.34% | -57.31% | -58.64% |
연결 기준 (백만 단위) / 별도 보기 가능
| Period (M) | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 0.38 | 0.3 | 0.3 | 0.26 | 3.73 | 0.41 | 15.32 | 77.8 | 132.56 | 234.04 |
COGS | 50.38 | 2 | 76.01 | 116.29 | 92.5 | 102.86 | 4.77 | 23.41 | 51.67 | 152.16 |
Gross Profit | 0.38 | -1.7 | 0.3 | 0.26 | -88.77 | -102.45 | 10.56 | 54.39 | 80.9 | 81.88 |
Gross Profit % | 100% | -565% | 100% | 100% | -2380.56% | -24805.81% | 68.88% | 69.91% | 61.03% | 34.98% |
| 52.43 | 72.62 | 79.46 | 117.76 | 146.36 | 164.87 | 283.72 | 329.06 | 353.07 | 398.65 | |
EBIT | -52.05 | -72.32 | -88.22 | -120.42 | -142.63 | -164.46 | -273.16 | -274.68 | -272.17 | -316.78 |
OPM % | -13590.08% | -24105.67% | -29405% | -45963.36% | -3824.99% | -39820.58% | -1782.46% | -353.06% | -205.31% | -135.35% |
Non-Operating Income | -10.87 | -1.16 | -1.05 | -0.16 | 3.07 | 5.03 | -11.55 | -6.63 | -83.55 | -6.91 |
PBT | -62.92 | -73.48 | -89.27 | -120.59 | -139.57 | -159.43 | -284.71 | -281.31 | -355.72 | -323.69 |
Income Tax | 8.39 | -1.13 | -0.9 | -1.54 | 3 | -3.21 | -2.62 | 5.51 | 0.7 | 0.3 |
Tax Rate % | -13.33% | 1.54% | 1.01% | 1.27% | -2.15% | 2.01% | 0.92% | -1.96% | -0.2% | -0.09% |
Net Income | -62.92 | -73.48 | -89.27 | -120.59 | -142.57 | -156.22 | -282.09 | -286.82 | -356.42 | -323.99 |
NPM % | -16427.42% | -24492% | -29756.67% | -46025.57% | -3823.22% | -37824.94% | -1840.71% | -368.68% | -268.87% | -138.43% |
연결 기준 (백만 단위) / 별도 보기 가능
| Period (M) | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| 171.03 | 201.62 | 63.5 | 282.9 | 73.26 | 171.16 | 333.56 | 110.62 | 108.97 | 137.33 | |
| 0.07 | 52.44 | 122.03 | 0 | 102.56 | 118.95 | 102.95 | 114.45 | 231.74 | 116.59 | |
| 19.27 | 19.71 | 10.59 | 9.25 | 14.45 | 14.76 | 17.5 | 69 | 67.75 | 0 | |
| 1.7 | 1.66 | 7.17 | 2.32 | 32.11 | 6.49 | 19.26 | 28.59 | 34.02 | 84.95 | |
| 0.39 | 0.4 | 1.08 | 1.24 | 3.98 | 28.93 | 246.96 | 208.5 | 139.42 | 139.59 | |
Total Assets | 192.47 | 275.82 | 204.36 | 295.7 | 226.35 | 340.29 | 720.22 | 531.16 | 581.9 | 478.45 |
| 0.02 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | 0.07 | 0.07 | 0.08 | 0.09 | |
| 176.34 | 253.22 | 177.04 | 268.81 | 145.59 | 225.44 | 374.22 | 68.4 | 12.52 | -151.69 | |
| 3.54 | 8.48 | 5.35 | 1.87 | 14.41 | 29.34 | 212.11 | 324.51 | 418.47 | 478.43 | |
| 3.6 | 3.35 | 4.42 | 7.51 | 8.97 | 29.6 | 44.24 | 48.44 | 58.99 | 67.63 | |
| 8.96 | 10.73 | 17.53 | 17.47 | 57.34 | 55.86 | 89.58 | 89.75 | 91.84 | 83.99 | |
Total Liabilities | 192.47 | 275.82 | 204.36 | 295.7 | 226.35 | 340.29 | 720.22 | 531.16 | 581.9 | 478.45 |
연결 기준 (백만 단위) / 별도 보기 가능
| Period (M) | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| -55.07 | -55.67 | -59.83 | -95.34 | -104.25 | -106.16 | -178.5 | -221.54 | -193.55 | -216.57 | |
| -6.9 | -56.34 | -75.5 | 118.79 | -107.03 | -17.59 | 12.13 | -29.66 | -138.8 | 0 | |
| 229.09 | 142.59 | -2.64 | 195.94 | 1.78 | 221.66 | 331.48 | 29.87 | 331.69 | 136.57 | |
Net CFNet Cash Flow | 167.12 | 30.58 | -137.97 | 219.39 | -209.49 | 97.9 | 165.11 | -221.33 | -0.65 | -80.01 |
FCFFree Cash Flow | -62.05 | -59 | -63.3 | -97.97 | -111.34 | -109.4 | -182.72 | -239.61 | -216.56 | -223.46 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| -668.6% | -34.2% | -41.5% | -54.1% | -68.8% | -84.2% | -94.1% | -129.6% | -879.3% | 466.2% | |
| 0.02 | 0.03 | 0.03 | 0.01 | 0.10 | 0.13 | 0.57 | 4.74 | 33.21 | -3.16 | |
| 16.87 | 21.10 | 9.81 | 13.65 | 6.50 | 7.24 | 7.38 | 3.66 | 4.95 | 3.80 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.03 | 0.12 | 0.24 | 0.44 | |
Cash Conversion | 0.88 | 0.76 | 0.67 | 0.79 | 0.73 | 0.68 | 0.63 | 0.77 | 0.54 | 0.67 |
Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| -37.9% | -21.7% | 0.0% | -12.7% | 1323.3% | -88.9% | 3610.7% | 407.7% | 70.4% | 76.5% | |
| - | - | - | - | - | - | - | - | - | - | |
| - | - | - | - | - | - | - | - | - | - | |
| 5.00 | 3.00 | 4.00 | 4.00 | 4.00 | 4.00 | 5.00 | 3.00 | 3.00 | 2.00 | |
| -2.21 | -2.49 | 27.10 | -3.99 | 44.50 | -4.97 | -160.41 | -0.01 | -2.36 | -2.14 | |
| 66.67 | 33.33 | 66.67 | 66.67 | 33.33 | 33.33 | 53.33 | 33.33 | 33.33 | 60.00 | |
| -164.3% | -244.9% | -297.6% | -460.3% | -38.2% | -378.2% | -18.4% | -3.7% | -2.7% | -1.4% |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Revance Therapeutics Inc의 주주 구성 (SEC 공시 기준)
Who owns the company, quarter by quarter
Calendar quarters (13F report dates). Jun 2026 can still change as late 13F amendments arrive.
| Shares held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | QoQ |
|---|---|---|---|---|---|---|---|---|---|
| 2.1M | 2.1M | 327.3K | 327.3K | 327.3K | 327.3K | 159.7K | 159.7K | 0 | |
ForeignForeign institutions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
USUS institutions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Govt.Government & pensions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of institutional holders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Insiders = officers, directors and 10% owners (Forms 3/4/5). Foreign vs US = the 13F manager's registered address. Government = sovereign funds, central banks and public pensions. Public includes retail investors and funds below the $100M 13F threshold. Named holders are the largest 13F filers each quarter; shares outstanding come from the 10-K / 10-Q cover page.
| Holder | Type | Based in | Shares | % of class | Latest filing |
|---|---|---|---|---|---|
| Investment adviser | DE | 0 | 0.00% | SC 13G/A · 15 May 2025 | |
| Investment adviser | DE | 0 | 0.00% | SC 13G/A · 15 May 2025 | |
| Holding company | DE | 0 | 0.00% | SC 13G/A · 6 Mar 2025 | |
| Holding company | X1 | 1,611,787 | 1.54% | SC 13G/A · 13 Feb 2025 | |
| Holding company | DE | 4,784,658 | 4.60% | SC 13G/A · 31 Oct 2024 |
Anyone owning more than 5% must file a Schedule 13D (active) or 13G (passive). Structured filings since December 2024; a holder that drops below 5% files an exit amendment. 13F still covers them in the shareholding table.
| Settlement date | Short shares | Change | Days to cover | Relative size |
|---|---|---|---|---|
| 31 Jan 2025 | 3,842,421 | -14.8% | 1.13 | |
| 15 Jan 2025 | 4,511,897 | -45.9% | 1.37 | |
| 31 Dec 2024 | 8,341,091 | -14.7% | 4.08 | |
| 13 Dec 2024 | 9,774,434 | -23.1% | 2.13 | |
| 29 Nov 2024 | 12,703,555 | +4.0% | 7.62 | |
| 15 Nov 2024 | 12,210,780 | +22.1% | 3.69 | |
| 31 Oct 2024 | 10,004,216 | +8.8% | 5.57 | |
| 15 Oct 2024 | 9,194,558 | -3.6% | 6.79 | |
| 30 Sep 2024 | 9,539,780 | +25.0% | 1.82 | |
| 13 Sep 2024 | 7,631,413 | +1.0% | 1.51 | |
| 30 Aug 2024 | 7,556,918 | -18.4% | 1.63 | |
| 15 Aug 2024 | 9,264,189 | -40.8% | 1.00 | |
| 31 Jul 2024 | 15,647,194 | -4.3% | 8.06 | |
| 15 Jul 2024 | 16,350,136 | +7.6% | 10.13 | |
| 28 Jun 2024 | 15,193,716 | +5.9% | 7.24 | |
| 14 Jun 2024 | 14,352,615 | +12.5% | 10.14 | |
| 31 May 2024 | 12,763,394 | +2.2% | 6.13 | |
| 15 May 2024 | 12,490,424 | +1.6% | 5.14 | |
| 30 Apr 2024 | 12,288,926 | +5.7% | 6.01 | |
| 15 Apr 2024 | 11,625,272 | -14.2% | 7.96 | |
| 28 Mar 2024 | 13,551,210 | +24.7% | 8.72 | |
| 15 Mar 2024 | 10,865,757 | -8.5% | 4.39 | |
| 29 Feb 2024 | 11,879,422 | -3.7% | 6.44 | |
| 15 Feb 2024 | 12,340,459 | -2.4% | 7.63 |
FINRA consolidated short interest, reported twice a month for every US listing.
Revance Therapeutics Inc의 SEC 공시 및 실적 발표 컨퍼런스콜 녹취록
What recent news says about Revance Therapeutics Inc, scored for sentiment.